Treatment of osteopenia and osteoporosis;Tratamiento de la osteopenia y la osteoporosis

Medicine

Volumn 10, Issue 92, 2011, Pages 6221-6229

  Del Pino Montes, J ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b RETICEF ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; OSTEOPENIA; OSTEOPOROSIS;

EID: 84856731695     PISSN: 03045412     EISSN: 15788822     Source Type: Journal    
DOI: 10.1016/S0304-5412(11)70247-5     Document Type: Article

References (56)

1. NIH Consensus Developmeent Panel on Osteoporosis prevention, diagnosis, and therapy. Jama. 2001;285:785-795.
2. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
3. J.A. Kanis, A. Oden, H. Johansson, F. Borgstrom, O. Strom, and E. McCloskey FRAX and its applications to clinical practice Bone 44 2009 734 743
4. J.A. Kanis, H. Johansson, A. Oden, and E.V. McCloskey Guidance for the adjustment of FRAX according to the dose of glucocorticoids Osteoporos Int 22 2011 809 816
5. S.B. Tanner Dual-energy X-ray absorptiometry in clinical practice: new guidelines and concerns Curr Opin Rheumatol 23 2011 385 388
6. E. Jódar Gimeno Comité del I Foro Multidisciplinar en el Paciente con Alto Riesgo de Fractura. Conclusiones consensuadas del I Foro Multidisciplinar en el manejo del paciente con Alto Riesgo de Fractura (ARF) Osteoporótica Rev Osteoporos Metab Miner 2 2010 75 82
7. J.A. Kanis, A. Oden, O. Johnell, H. Johansson, C. De Laet, and J. Brown The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women Osteoporos Int 18 2007 1033 1046 (Pubitemid 47020000)
8. J. González Macías, N. Guañabens Gay, C. Gómez Alonso, L. del Río Barquero, M. Muñoz Torres, and M. Delgado Guías de práctica clínica en la osteoporosis postmenopáuisca, glucocorticoidea y del varón. Sociedad Española de Investigación Ósea y del Metabolismo Mineral Rev Clin Esp. 28 Supp1) 2008 1 24
9. J. Compston, A. Cooper, C. Cooper, R. Francis, J.A. Kanis, and D. Marsh Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Maturitas 62 2009 105 108
10. J. Kanis, E. McCloskey, C. Johansson, A. Oden, O. Ström, and F. Borgström Development and use of FRAX® in osteoporosis Osteoporos Int 21Suppl2 2010 S407 S413
11. J.A. Kanis, O. Johnell, A. Oden, H. Johansson, and E. McCloskey FRAX and the assessment of fracture probability in men and women from the UK Osteoporos Int 19 2008 385 397
12. J.M. Grossman Osteoporosis prevention Curr Opin Rheumatol 23 2011 203 210
13. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011:CD000333.
14. Warensjo E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A, et al. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ.2011;342:d1473.
15. M.J. Bolland, A. Avenell, J.A. Baron, A. Grey, G.S. MacLennan, and G.D. Gamble Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis BMJ 341 2010 c3691
16. J.E. Manson, M.A. Allison, J.J. Carr, R.D. Langer, B.B. Cochrane, and S.L. Hendrix Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative Menopause 17 2010 683 691
17. A.J. Lanou, and N.D. Barnard Dairy and weight loss hypothesis: an evaluation of the clinical trials Nutr Rev 66 2008 272 279 (Pubitemid 351623970)
18. L.A. van Mierlo, L.R. Arends, M.T. Streppel, M.P. Zeegers, F.J. Kok, and D.E. Grobbee Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials J Hum Hypertens 20 2006 571 580 (Pubitemid 44088959)
19. P. Autier, S. Gandini, and Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials Arch Intern Med 167 2007 1730 1737 (Pubitemid 47403059)
20. M. Moro-Álvarez, and M. Diaz-Curiel Tratamiento de la oseoporosis con bisfosfonatos Medicne (Madrid) 60 2010 4135 4143
21. J.A. Kanis, H. Johansson, A. Oden, and E.V. McCloskey Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX Bone 44 2009 1049 1054
22. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. En prensa. 2011.
23. S. Boonen, J.D. Adachi, Z. Man, S.R. Cummings, K. Lippuner, and O. Törring Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk J Clin Endocrinol Metab 96 2011 1727 1736
24. P.D. Miller, R.B. Wagman, M. Peacock, E.M. Lewiecki, M.A. Bolognese, and R.L. Weinstein Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial J Clin Endocrinol Metab 96 2011 394 402
25. S.A. Jamal, O. Ljunggren, C. Stehman-Breen, S.R. Cummings, M.R. McClung, and S. Goemaere Effects of denosumab on fracture and bone mineral density by level of kidney function J Bone Miner Res 26 2011 1829 1835
26. X. Nogués Solán Tratamiento de la osteoporosis con fármacos osteoformadores y otros Medicine (Madrid) 10 2010 4144 4148
27. J.Y. Reginster, O. Bruyere, A. Sawicki, A. Roces-Varela, P. Fardellone, and A. Roberts Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years Bone 45 2009 1059 1064
28. Kanis JA, Johansson H, Oden A, McCloskey EV. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int. En prensa. 2011.
29. J. Farrerons, and R. Pérez Cano Tratamiento de la osteoporosis postmenopáusica con combinación de fármacos Medicine (Madrid) 10 2010 461 466
30. F. Cosman, J. Nieves, L. Woelfert, C. Formica, S. Gordon, and V. Shen Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal J Bone Miner Res 16 2001 925 931 (Pubitemid 32332303)
31. R. Lindsay Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE) Osteoporos Int 22 2 2011 447 451
32. M.J. Bolland, A.B. Grey, G.D. Gamble, and I.R. Reid Effect of osteoporosis treatment on mortality: a meta-analysis J Clin Endocrinol Metab 95 2010 1174 1181
33. I.R. Reid Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies Skeletal Radiol 40 2011 1191 1196
34. D.M. Black, A.V. Schwartz, K.E. Ensrud, J.A. Canley, S. Levis, and S.A. Oyvand Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial Jama 296 2006 2927 2938 (Pubitemid 46021497)
35. Eastell R, Hannon RA, Wenderoth D, Rodríguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab. En prensa 2011.
36. C.V. Odvina, J.E. Zerwekh, D.S. Rao, N. Maalouf, F.A. Gottschalk, and C.Y. Pak Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 2005 1294 1301 (Pubitemid 40463979)
37. D.H. Solomon, L. Rekedal, and S.M. Cadarette Osteoporosis treatments and adverse events Curr Opin Rheumatol 21 2009 363 368
38. S.L. Silverman, and R. Landesberg Osteonecrosis of the jaw and the role of bisphosphonates: a critical review Am J Med 122 2009 S33 S45
39. M. Sosa Henríquez, J. Bagan, M. Diaz Curiel, A. Díez-Pérez, M.J. Gómez de Tejada, and E. Jódar Gimeno Osteonecrosis de los maxilares: Documento de consenso de la SEIOMM conjuntamente con la SER Rev Osteoporos Metab Miner 1 2009 41 51
40. A. Grey Teriparatide for bone loss in the jaw N Engl J Med 363 25 2010 2458 2459
41. E. Shane, D. Burr, P.R. Ebeling, B. Abrahamsen, R.A. Adler, and T.D. Brown Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 25 2010 2267 2294
42. J. Schilcher, K. Michaelsson, and P. Aspenberg Bisphosphonate use and atypical fractures of the femoral shaft N Engl J Med 364 2011 1728 1737
43. R. Rizzoli, K. Akesson, M. Bouxsein, J.A. Kanis, N. Napoli, and S. Papapoulos Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report Osteoporos Int 22 2 2011 373 390
44. D.E. Sellmeyer Atypical fractures as a potential complication of long-term bisphosphonate therapy Jama 304 2010 1480 1484
45. A. SebbaF Osteoporosis: how long should we treat? Curr Opin Endocrinol Diabetes Obes 15 2008 502 507
46. N.B. Watts, and D.L. Diab Long-term use of bisphosphonates in osteoporosis J Clin Endocrinol Metab 95 2010 1555 1565
47. A. Diez-Pérez, and J. González-Macías Inadequate responders to osteoporosis treatment: proposal for an operational definition Osteoporos Int 19 2008 1511 1516
48. S.R. Cummings, L. Palermo, W. Browner, R. Marcus, R. Wallace, and J. Pearson Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group Jama 283 2000 1318 1321 (Pubitemid 30129799)
49. J.J. Carey What is a 'failure' of bisphosphonate therapy for osteoporosis? Cleve Clin J Med 72 2005 1033 1039
50. C. Kok, and P.N. Sambrook Secondary osteoporosis in patients with an osteoporotic fracture Best Pract Res Clin Rheumatol 23 2009 769 779
51. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. En prensa 2011.
52. A.H. Warriner, and J.R. Curtis Adherence to osteoporosis treatments: room for improvement Curr Opin Rheumatol 21 2009 356 362
53. Fahrleitner-Pammer A, Langdahl BL, Marin F, et al. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int. En prensa. 2011.
54. www.ibmsonline.org/p/cm/ld/fid=1
55. www.iofbonehealth.org
56. www.seiomm.org